Catarina Barros

Catarina Barros

Auto-generated profile, based on publicly available information

Catarina Barros

Research Institute for Medicines (iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, 1649-003 Lisbon, Portugal

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2021 in Cells
Verified
Journal Article
Open access
PDF file
Maria Vaz PintoMaria Vaz Pinto
Maria Vaz Pinto
FSFábio M. F. Santos
Fábio M. F. Santos
CBCatarina Barros
Catarina Barros
ARAna Rita Ribeiro
Ana Rita Ribeiro
UPUwe Pischel
Uwe Pischel
Adelaide FernandesAdelaide Fernandes
Adelaide Fernandes
Multiple sclerosis (MS) is a demyelinating disease of the central nervous system that is characterized by the presence of demyelinated regions with accumulated myelin lipid debris. Importantly, to allow effective remyelination, such debris must be cleared by microglia. Therefore, the study of microglial activity with sensitive tools is of great interest to better monitor the MS clinical course. Using a boronic acid-based (BASHY) fluorophore, specific for nonpolar lipid aggregates, we aimed to address BASHY’s ability to label nonpolar myelin debris and image myelin clearance in the context of demyelination. Demyelinated ex vivo organotypic cultures (OCSCs) and primary microglia cells were immunostained to evaluate BASHY’s co-localization with myelin debris and also to evaluate BASHY’s specificity for phagocytosing cells. Additionally, mice induced with experimental autoimmune encephalomyelitis (EAE) were injected with BASHY and posteriorly analyzed to evaluate BASHY+ microglia within demyelinated lesions. Indeed, in our in vitro and ex vivo studies, we showed a significant increase in BASHY labeling in demyelinated OCSCs, mostly co-localized with Iba1-expressing amoeboid/phagocytic microglia. Most importantly, BASHY’s presence was also found within demyelinated areas of EAE mice, essentially co-localizing with lesion-associated Iba1+ cells, evidencing BASHY’s potential for the in vivo bioimaging of myelin clearance and myelin-carrying microglia in regions of active demyelination.

1 March 2020 in Journal of Neuroimmunology
Verified
Journal Article
Closed access
SNSofia Pereira Das Neves
Sofia Pereira Das Neves
GSGisela Santos
Gisela Santos
CBCatarina Barros
Catarina Barros
DPDiana Rodrigues Pereira
Diana Rodrigues Pereira
RFRicardo Ferreira
Ricardo Ferreira
JCJoao Jose Cerqueira
Joao Jose Cerqueira

1 May 2018 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
CBC. Barros
C. Barros
PPP. Pascoal
P. Pascoal
GSG. Santos
G. Santos
ABA. Barateiro
A. Barateiro
RFR. Freitas
R. Freitas
AFA. Fernandes
A. Fernandes

1 January 2019 in Frontiers in Cellular Neuroscience
Verified
Journal Article
Open access
ABAndreia Barateiro
Andreia Barateiro
CBCatarina Barros
Catarina Barros
BSBeatriz Soromenho
Beatriz Soromenho
ABAfonso P. Basto
Afonso P. Basto
RFRaquel Freitas
Raquel Freitas
AFAdelaide Fernandes
Adelaide Fernandes
Multiple Sclerosis (MS), an autoimmune and chronic demyelinating disease of the CNS, cause physical and cognitive disability in young adults. The experimental autoimmune encephalomyelitis (EAE), most common animal model for MS, is based on CD4+/CD8+ T-cell mediated self-reaction against components of myelin. These cells along with microglia recruit other immune cells from the circulating blood, leading to inflammation, gliosis, focal demyelination and neurological affections, major hallmarks of the disease. Interestingly, S100B, a small inflammatory molecule, is increased in the CSF and serum of MS patients. Recently, we directly correlated increased levels of S100B with demyelination and inflammatory processes, using an ex vivo demyelination model, where S100B inhibition by a small molecule showed promising results. Here, we aimed to assay whether S100B targeting with a small molecule in the EAE model could ameliorate MS-like pathogenesis. EAE was induced in female C57BL/6J wild-type mice and two groups were formed: vehicle group (saline) and EAE-treated group (small molecule, 4mg/kg, i.p., daily). Then, we evaluated clinical score and body weight during 30-days of experiments, immune cell response at the peak of the disease (around 14 days) and CNS pathogenesis at end-point. Our results demonstrated that disease was delayed in EAE animals following treatment with a small molecule, reaching a lower clinical score and having a faster recovery, which is corroborated by less motor disability. In EAE-induced animals was observed increased percentage of demyelination, which was counteracted upon treatment with a small molecule. Moreover, EAE-treated animals also showed reduction of astrocyte and microglia reactivity, leading to the prevention of the exacerbated expression of inflammatory factors (TNF-α/IL-1β) and increasing that anti-inflammatory ones (IL-10). Furthermore, preliminary data show that, EAE-treated animals have a reduced cell infiltration in lumbar and thoracic regions of the spinal cord. Interestingly, at the peak of the disease EAE-treated animals also showed a decreased percentage of Th1 and Th17 cells alongside with decreased Th17/Treg ratio. Overall, our results indicate that S100B is involved in MS pathology both with an effect at CNS resident cells as well as at the immune cells, suggesting that its inhibition may be a new therapeutic strategy acting at different mechanisms of MS pathogenesis.